As of June 21, coronavirus SARS-CoV-2 has infected almost 9 milions of people and the number of laboratory-confirmed COrona-VIrus Disease 2019 (COVID-19) deaths are 461,715, worldwide [@b0005]. The virus causes acute respiratory distress syndrome (SARS) and, eventually, death from multiple organ failure, in a non-neglectable portion of patients [@b0010]. As such, COVID-19 is an international public health emergency. Although some recent reports suggested the efficacy of diverse agents, there is currently no standard therapy for COVID-19.

Several preclinical studies showed that doxycycline (DOX) and minocycline (MIN), semi-synthetic tetracyclines frequently used in clinical practice against a variety of infective agents and well tolerated, are also effective against some RNA viruses [@b0015], [@b0020]. It is commonly recognized that tetracyclines act selectively inhibiting microbial protein synthesis by binding to the 16S rRNA [@b0025]. Recent evidence suggested that the precise site of interaction between DOX/MIN and 16S rRNA as well as other cellular RNA molecules could be double-stranded RNAs (dsRNAs) [@b0030]. The dsRNA-binding mechanism could explain the tetracyclines broad antimicrobial and antiviral properties [@b0030]. Indeed, rRNAs form numerous double-stranded structures that are essential to protein synthesis. Furthermore, dsRNAs have been observed as intermediates of the viral replication of positive-stranded viruses, including SARS coronaviruses [@b0035], [@b0040]. SARS-CoV-2 is a positive-stranded RNA virus and, interestingly, DOX/MIN antiviral efficacy was hitherto reported mostly against positive-sense RNA viruses [@b0015], [@b0020]. Besides, replication of RNA viruses occurs in the host cell cytoplasm, where Mg + concentration is most favorable to DOX/MIN binding [@b0025]. As such, DOX/MIN may be effective also against SARS-CoV-2 infection. In this regard, accumulating evidence shows that SARS is associated with an aberrant induction of inflammatory cytokines/chemokines, mostly activated by dsRNA intermediates of viral replication [@b0045], [@b0050]. In particular, the robust viral replication and delayed IFN-γ signaling accompanying the initial steps of SARS seem to be consequence of the coronavirus ability to initially evade the host dsRNA-sensors [@b0050], [@b0055]. Therefore, it is plausible that early administration of dsRNA-binding DOX/MIN may reduce the risk of SARS. This hypothesis is strengthened by the fact that both DOX and MIN are known to have relevant anti-inflammatory properties [@b0060]. In detail, the tetracyclines inhibit pro-inflammatory cytokines and matrix metalloproteinases that play a key role in coronavirus acute infection and are involved in chemokine activation and in tissue destruction, such as perivascular basement membrane and parenchymal extracellular matrix, thereby facilitating inflammatory cells infiltration [@b0060], [@b0065]. Of note, also this immunomodulatory effect seems to be dsRNA-mediated [@b0025]. Hence, DOX/MIN may inhibit both the viral replication and the host exuberant inflammatory response. Taken together, all evidence suggests that DOX/MIN may be active against SARS-CoV-2 and clinical trials investigating these drugs are urgently warranted.
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